Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Aquestive Therapeutics, Inc. Common Stock (AQST)

Pharmaceutical Preparations

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

30 TECHNOLOGY DRIVE
WARREN, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/25/2018

Market Cap

382,906,459

Shares Outstanding

66,769,999

Weighted SO

66,767,283

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

EVOK --.--%

ADMP --.--%

GHSI --.--%

ACRX --.--%

DVAX --.--%

AMPH --.--%

LNTH --.--%

ANIP --.--%

IRWD --.--%

Beta

2.7940

Last Div

0.0000

Range

1.251-6.23

Chg

0.0850

Avg Vol

1505083

Mkt Cap

382906459

Exch

NASDAQ

Country

US

Phone

908 941 1900

DCF Diff

10.0871

DCF

-4.7471

Div Yield

0.0000

P/S

6.5611

EV Multiple

-28.6437

P/FV

-10.7749

Div Yield %

0.0000

P/E

-14.8639

PEG

-0.1660

Payout

0.0000

Current Ratio

7.4855

Quick Ratio

6.9842

Cash Ratio

6.4678

DSO

37.5132

DIO

138.2443

Op Cycle

175.7575

DPO

113.0405

CCC

62.7171

Gross Margin

0.6849

Op Margin

-0.2603

Pretax Margin

-0.4414

Net Margin

-0.4407

Eff Tax Rate

-0.0048

ROA

-0.2187

ROE

0.3659

ROCE

-0.1465

NI/EBT

0.9985

EBT/EBIT

1.6957

EBIT/Rev

-0.2603

Debt Ratio

0.9493

D/E

-3.1468

LT Debt/Cap

1.4750

Total Debt/Cap

1.4658

Int Coverage

-4.4676

CF/Debt

-0.2210

Equity Multi

-3.3148

Rec Turnover

9.7299

Pay Turnover

3.2289

Inv Turnover

2.6403

FA Turnover

6.2377

Asset Turnover

0.4962

OCF/Share

-0.2715

FCF/Share

-0.2740

Cash/Share

0.9885

OCF/Sales

-0.4229

FCF/OCF

1.0094

CF Coverage

-0.2210

ST Coverage

-16.6863

CapEx Coverage

-106.8355

Div&CapEx Cov

-106.8355

P/BV

-10.7749

P/B

-10.7749

P/S

6.5611

P/E

-14.8639

P/FCF

-15.3716

P/OCF

-15.4902

P/CF

-15.4902

PEG

-0.1660

P/S

6.5611

EV Multiple

-28.6437

P/FV

-10.7749

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 17, 18:15 Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors Zacks Investment Research Dec 26, 09:29 What Awaits These 4 Drug Stocks That More Than Doubled in 2023? GlobeNewswire Inc. Nov 06, 16:37 Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update GlobeNewswire Inc. Nov 06, 16:37 Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Revenue Product Segmentation